Rather than looking at the global deposition of beta-amyloid in the brain, it may be more valuable to analyze its spatial pattern, now thought to have a stronger association with memory decline, according to a study published July 15 in Neurobiology of Aging.

Amyloid imaging has been the single stitch holding Alzheimer’s imaging together even though beta-amyloid plaque is typically interwoven in the brain with tangles of tau proteins, but that may soon change as two new tau radiotracers tighten the knit of novel dementia imaging, according to a study published July 15 in the Journal of Nuclear Medicine.

C-11 flumazenil (FMZ) PET has been found to have superior localizing specificity compared with F-18 FDG PET for patients with refractory focal epilepsy. However, there are logistical limitations inherent in the use of C-11. A promising potential alternative is F-18 FMZ, according to a study published July 15 in the Journal of Nuclear Medicine.

RadNet Inc. (Nasdaq:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 248 subsidiary-owned and/or operated outpatient imaging centers, announced its participation in a clinical trial to evaluate the biomarker effects of the investigational drug E2609, a BACE inhibitor, which is being developed for the potential disease modifying treatment of Alzheimer's disease (AD).

Evaluation of adrenal nodules with F-18 FDG PET/CT was given a mean score of 93 percent diagnostic accuracy with an almost equally high percentage of interreader agreement, suggesting subjective visual interpretation is an effective method of evaluation, according to a review published in the August issue of Academic Radiology.

Adjuvant chemotherapy may not be the best option for patients with certain subtypes of breast cancer who show no clear benefit, according to an extensive retrospective of four clinical trials published June 12 in Breast Cancer Research and Treatment.

Radioimmunotherapy with Lu-177 DOTA-rituximab represents a novel and well-matched treatment for B-cell Lymphoma, but no consensus on standardized dosimetry was available, until now, according to research published in the July issue of Journal of Nuclear Medicine.

Personalized therapy assessment for Hodgkin lymphoma (HL) with interim FDG PET could help step up or step down treatment to find the curative sweet spot, but the transition from PET-adaptive clinical trials to practice requires additional time to prove broad benefit for patients, according to a review published July 1 in the Journal of Nuclear Medicine.